



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Brief assessment of male depression in clinical care: Validation of the Male Depression Risk Scale Short Form in a cross-sectional study of Australian men

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053650
Article Type:	Original research
Date Submitted by the Author:	23-May-2021
Complete List of Authors:	Herreen, Danielle; The University of Adelaide School of Psychology, ; Commonwealth Scientific and Industrial Research Organisation, Health & Biosecurity Rice, Simon; Orygen Youth Health; The University of Melbourne Centre for Youth Mental Health Zajac, Ian ; Commonwealth Scientific and Industrial Research Organisation, Health & Biosecurity
Keywords:	Depression & mood disorders < PSYCHIATRY, PRIMARY CARE, Suicide & self-harm < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Brief assessment of male depression in clinical care:**

**Validation of the Male Depression Risk Scale Short Form in a cross-sectional study of  
Australian men**

Danielle Herreen<sup>1, 2 \*</sup>, Simon Rice<sup>3, 4</sup>, & Ian Zajac<sup>2</sup>

<sup>1</sup> School of Psychology, University of Adelaide, Adelaide, SA 5000 Australia

<sup>2</sup> Health & Biosecurity, Commonwealth Scientific & Industrial Research Organisation  
(CSIRO), Adelaide, SA 5000, Australia

<sup>3</sup> Orygen, Parkville, VIC 3052, Australia

<sup>4</sup> Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC 3052,  
Australia

\* Corresponding author information: Danielle Herreen, School of Psychology, University of  
Adelaide, Adelaide, SA 5000, Australia (email: [danielle.herreen@adelaide.edu.au](mailto:danielle.herreen@adelaide.edu.au))

**Word Count: 3670**

Abstract

**Objectives:** To develop and validate a short form of the Male Depression Risk Scale (MDRS-22) for use in primary care, examining sensitivity indices for psychological distress and suicidality.

**Design:** Cross-sectional study with 8-month follow-up.

**Setting:** Community-based recruited via an online survey.

**Participants:** A community sample of younger ( $n = 514$ ; 18-64 years) and older ( $n = 444$ ; 65-93 years) males residing in Australia ( $M$  age = 58.11 years,  $SD = 17.73$ ) completed measures of externalising and prototypic depression symptoms. A subset of respondents ( $n = 167$  younger males;  $n = 173$  older males) provided follow-up data approximately eight months later.

**Primary and secondary outcome measures:** Participants completed the Male Depression Risk Scale (MDRS-22), Patient Health Questionnaire (PHQ-9), and Kessler Psychological Distress Scale (K10). Probable depression was determined according to PHQ-9 scores  $\geq 10$ . Suicidality was determined based on a score  $\geq 1$  on item 9 of the PHQ-9. Probable mental illness was determined based on a K10 score  $\geq 25$ .

**Results:** The short form MDRS-22 consisted of seven items (MDRS-7) and captured all of the domains in the original tool. Results demonstrated that externalising symptoms, either alone or in combination with prototypic symptoms were significantly more common than exclusively prototypic symptoms. Participants in the mixed symptom group had significantly higher risk of mental illness and current suicidality. Furthermore, the MDRS-7 was shown to be effective at predicting elevated symptoms of depression at follow-up, after controlling for previous depression diagnoses.

**Conclusions:** Findings provide preliminary evidence of the potential utility of the MDRS-7 as a screening tool for externalised symptoms associated with major depression in men. Use of the MDRS-7 in primary care settings may facilitate identification of men at-risk of suicide and psychological distress who do not meet cut-off scores for existing measures of major depression symptoms.

**Key words:** depression, externalising symptoms, short form, men, lifespan, help-seeking

### Strengths and limitations of this study:

- This is the first study to explore the psychometric properties of the MDRS-7 as a screening tool for externalised symptoms associated with major depression in men.
- Use of the MDRS-7 in primary care settings may facilitate identification of men at risk of suicide and psychological distress.
- Diagnosis of depression was not verified by clinical interview.
- Field trials of the MDRS-7 are needed to demonstrate the utility of the tool in primary care settings.

### Introduction

Major depressive disorder (MDD) is a common psychiatric condition and the leading cause of disability worldwide [1, 2]. MDD is twice as prevalent in women than men [3] and severe depression is known to significantly increase the risk of suicide [4]. Although men are less likely to be diagnosed with a depressive disorder [5], they are three times more likely to die by suicide compared to women [6]. Current approaches to the diagnosis of depression (e.g., as per ICD-11 or DSM-5 diagnostic criteria) emphasise symptoms including persistent sadness, loss of interest or pleasure in previously enjoyable activities, as well as changes in affect, cognition, and neurovegetative functioning [7, 8]. However, a growing number of studies suggest that a significant proportion of men suffering from depression might experience a distinct phenotype [9-11]. Congruent with masculine role norms, this male-typical phenotype includes anger, substance misuse, emotion suppression, and risk-taking domains [10, 12]. However, these putative symptoms are not included in standard diagnostic criteria or screening measures, and it has been suggested that this might account in part for the under-diagnosis of male depression cases, and therefore under-recognition of (and treatment for) men at heightened risk of suicide [13].

Whilst men are often regarded as being less likely to seek help than women, recent statistics largely do not support this claim. In Australia, it has been estimated that in the general population, around 89% of men attend primary care annually [14]. Among men experiencing mental health difficulties, annual primary care attendance is similarly high with estimates of 80% up to 96% of men with symptoms of depression reporting a visit to

1  
2  
3 100 primary care within the previous 12 months [15, 16]. Similarly, findings from the UK  
4  
5 101 demonstrate that whilst males are overall less likely to attend primary care compared to  
6  
7 102 females, attendance rates in men and women with comparable underlying morbidities,  
8  
9 103 including depression, are similar [17]. Furthermore, findings from a population study of  
10  
11 104 health care contacts among Canadian suicide decedents in Toronto also demonstrated that  
12  
13 105 over 60% ( $n = 1792$ ) of men who died by suicide accessed professional mental health care in  
14  
15 106 the year before their death [18]. These findings highlight the essential role of primary care  
16  
17 107 physicians in identifying depression and suicide risk in men in order to facilitate effective  
18  
19 108 treatment [19].

20 109 Growing interest in gender-sensitive assessment of men’s depression has seen the  
21  
22 110 development of male-specific screening tools to identify symptoms that align with men’s  
23  
24 111 socialisation and gender norm processes [e.g., 20, 21, 22]. One recently developed and  
25  
26 112 widely validated measure for assessing externalising symptoms in men is the Male  
27  
28 113 Depression Risk Scale (MDRS-22) [23]. The MDRS-22 consists of 22 items assessing six  
29  
30 114 symptom domains including emotion suppression, drug use, alcohol use, anger and  
31  
32 115 aggression, somatic symptoms, and risk-taking [23]. Recently, Zajac and colleagues [24]  
33  
34 116 demonstrated that this tool, used in conjunction with a measure of prototypic major  
35  
36 117 depression symptoms (PHQ-9), was able to stratify men into three distinct risk groups: (i)  
37  
38 118 prototypic symptoms (consistent with current MDD diagnostic criteria), (ii) externalising  
39  
40 119 symptoms consistent with masculine socialisation, and (iii) mixed depressive symptoms,  
41  
42 120 reflecting both internalised and externalised symptomology. Further analyses showed that  
43  
44 121 men in the externalising only group—men who are arguably missed when using measures of  
45  
46 122 internalising symptoms—were at significantly increased risk of suicide compared to non-  
47  
48 123 depressed men. Moreover, those with elevated externalised and prototypic symptomology  
49  
50 124 were at highest risk of mental illness as well as suicide [24], highlighting the potential of  
51  
52 125 early identification and intervention benefits of leveraging male-specific tools in primary  
53  
54 126 care settings.

55 127 Two-stage screening methods are commonly used in primary care, and have been  
56  
57 128 shown to be effective for increasing the recognition of depression [25]. However, many  
58  
59 129 primary care physicians report that time is a limiting factor in their capacity to  
60

comprehensively assess psychological issues, including depression [19, 26], despite management of common mental disorders rating as a top reason for general practice attendance [27]. To help address this issue, brief screening tools consisting of 15 items or less are often used, given their completion time is usually just a couple of minutes [28]. Examples include the Patient Health Questionnaire (PHQ-9) [29], the Kessler Psychological Distress Scale (K10) [30], and the Beck Depression Inventory for Primary Care (BDI-PC) [31].

To date, the MDRS-22 has demonstrated excellent psychometric properties as well as the ability to detect different groups of men who may be at increased risk of suicide and mental illness [e.g., 24, 32, 33]. However, given time constraints in primary care settings, the length of the current MDRS-22 is arguably impractical [12]. The purpose of the present study was to develop a short form of the MDRS-22 to facilitate its use as a screening tool in busy and time-pressured health care settings. We also aimed to establish an initial set of cut-off scores for interpretive purposes, as well as examine current and longitudinal risk of suicidality and mental illness in subgroups. Furthermore, as adherence to masculine gender norms has been found to decline as men get older [34], younger and older males were examined separately to examine the utility of the tool across age groups.

## Method

### Participants and procedure

This cross-sectional study included baseline data from a community sample of 514 younger males aged 18 to 64 years ( $M = 45.46$ ,  $SD = 14.52$ ) and 444 older males aged 65 to 93 years ( $M = 72.75$ ,  $SD = 5.86$ ). A subset of respondents ( $n = 167$  younger males;  $n = 173$  older males) participated in the follow-up component. On average, 35 weeks ( $M = 247.94$  days,  $SD = 24.47$  days) elapsed between the provision of T1 and T2. The mean age for the overall sample was 58.11 years ( $SD = 17.73$ ). Eligible participants were Australian male residents over the age of 18 years who considered themselves fluent in English. Participants were recruited via paid advertisements displayed to Australian members of the Facebook social networking site ( $n = 609$ ; 63.6%) and through promotion of the study to community organisations (e.g., Rotary, Men's Shed). Time 1 (T1) data were collected between August and November 2019 using an online questionnaire. However, participants from local



community organisations were provided with the option to complete a paper version of the survey to ensure inclusivity and accessibility of the sample and  $n = 5$  participants completed a paper version. Ethics approval was obtained from the University of Adelaide Human Research Ethics Committee and the CSIRO Health and Medical Human Research Ethics Committee (approval number H-2019-109). All participants provided informed consent. Reporting adhered to the STROBE cross-sectional guidelines.

**Public involvement**

Participants were not involved in the design or conduct of this research; however, participants could nominate to receive updates on the results of the study.

**Measures**

***Demographics***

Participants reported their age, gender, relationship status, employment status, level of education, and household income.

***Male Depression Risk Scale (MDRS-22)***

Externalising depression symptoms were assessed by the Male Depression Risk Scale (MDRS-22) [23]. The MDRS-22 contains twenty-two self-report items designed to assess six broad domains of externalising and male-specific depression symptoms present in the last month including anger and aggression, drug use, alcohol use, emotion suppression, risk-taking, and somatic symptoms using the response format of 5-point Likert scale ranging from 0 (*none of the time*), 1 (*a little of the time*), 2 (*some of the time*), 3 (*most of the time*), and 4 (*all of the time*). Cronbach’s alphas for the MDRS are reported in Table 3 for both age groups and for the overall sample and are considered adequate.

***The Patient Health Questionnaire (PHQ-9)***

The Patient Health Questionnaire (PHQ-9) [29] is a self-report depression screening tool for use in primary care that assesses nine symptoms consistent with the DSM-5 diagnostic

criteria for major depressive disorder [7]. Participants endorse how often they have experienced each symptom (e.g., “*Feeling down, depressed, or hopeless*”) during the preceding two-week period using a 4-point Likert scale ranging from 0 (*not at all*) to 3 (*almost every day*). A score of 10 and above is indicative of clinically significant depressive symptoms [35]. In addition to utilising total PHQ-9 scores, we used item 9 as a measure of suicidality: “Over the past two weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself in some way?”. We deemed those who scored 1 or more on this item to be currently experiencing suicidal ideation. Internal consistency of the PHQ-9 in the present study for the overall sample was high ( $\alpha = .93$ ).

### ***Kessler Psychological Distress Scale (K10)***

The Kessler Psychological Distress Scale (K10) [30] is a widely used measure in both research and primary care settings [36]. It comprises ten questions assessing a person’s negative emotional state in the preceding 30 days (e.g., “*About how often did you feel so nervous that nothing could calm you down*”). Responses are based on a 5-point Likert scale ranging from 1 (*none of the time*) to 5 (*all of the time*). In addition to examining K10 total scores, we created a binary variable with scores  $\geq 25$  indicating probable mental illness, consistent with published cut-off scores for the K10 [37]. Internal consistency of the K10 in this study for the overall sample was high ( $\alpha = .95$ ).

### **Statistical analyses**

Data for the present study was analysed using IBM SPSS Statistics (Version 26.0) except for the Confirmatory Factor Analysis undertaken in JASP [Version 0.13.1; 38]. A total of 1114 participants commenced the study. However, 156 participants were not included in the analyses due to substantial missing data. Thus,  $N = 958$  participants who provided complete data for the items comprising the MDRS-22 were included in the item reduction process described below. Of this sample,  $n = 29$  did not provide complete data for the PHQ-9 or K10 items. Thus, models using these variables comprised  $n = 929$  participants.

Various recommendations exist for the selection of items for short-form surveys [39, 40]. Broadly speaking, the focus is on selecting items with maximum variability and which

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

retain the theorised underlying construct—as well as sub-domains—measured by the long-form scale. Therefore, we calculated descriptive (means, standard deviation (*SD*), and skewness) and relational statistics (correlations) for each item (see Table 2). Items were scored for each statistic (i.e., largest *SD*, strongest correlation etc) and summed across the statistical indices to derive a total score for each item. Best performing items were subject to Exploratory Factor Analysis with Maximum Likelihood Estimation performed within each age group, and in the combined sample. Parallel Analysis consisting of 1,000 permutations of the original raw data was used to determine thresholds for retaining factors. Stability of this solution was then established using Confirmatory Factor Analysis of Time 2 Data (*n* = 340). Fit indices reported include: comparative fit index (CFI); the Tucker-Lewis index (TLI); the root mean square error of approximation (RMSEA); and the standardized root mean residual (SRMR). Interpretation of these indices were guided by the recommendations of Hu & Bentler [41].

In order to demonstrate clinical utility of the reduced item scale, cut-off scores were determined for Low (0 – 5), Moderate (6 – 7), Severe (8 – 12) and Extremely severe (13+) symptom severity groups. These scores corresponded to cut-off percentiles representing differing degrees of increased risk of recent suicide attempt previously identified for the MDRS-22 [33]. Individuals were then classified into depression groups using the MDRS-7 in combination with the PHQ-9 as follows: not depressed (PHQ-9 < 10 and MDRS-7 ≤ 5), prototypical depression features (PHQ-9 ≥ 10 and MDRS-7 ≤ 5), mixed features (PHQ-9 ≥ 10 and MDRS-7 > 5) and externalising features (PHQ-9 < 10 and MDRS-7 > 5). In addition, the K10 was used to determine those individuals suffering a moderate mental illness (K10 ≥ 25) from those without a mental illness (K10 < 25), and current suicidality was ascribed based on scores ≥ 1 on PHQ-9 item 9: “Over the past two weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself in some way?”. Finally, Generalised linear models (GLMs) were used to examine differences in K10 and PHQ-9 scores across the MDRS-7 categories to determine risk of mental illness and current suicidality and to examine risk of Depression at Time 2 (PHQ-9 ≥ 10). Assumptions of GLMs were considered through inspection of scatter plots and histograms of residuals and predicted values, with model results reported as standardised betas.

## Results

### *Sample characteristics*

Table 1 presents the characteristics of the study participants at T1. As expected, there was a higher proportion of older participants who reported themselves as married/de-facto or widowed/divorced/separated, in comparison to younger men. Regarding education, the majority of older participants completed year 11 or below, whilst the proportion of participants completing a Bachelor's degree was higher in the younger sample. In addition, household income appeared to be higher in younger compared to older men, consistent with the majority of the older sample reporting themselves as being retired.

Insert Table 1 about here

### *Item reduction*

Descriptive and relational statistics for each of the MDRS-22 items across younger and older age groups are displayed in Supplementary Table 1. For the emotion suppression, alcohol use, somatic symptoms, and drug use domains, a single highest scoring item emerged congruent across age groups. For the anger and aggression domain, two different items were retained because of their performance across the age groups. Finally, although two risk-taking items scored equally well in the younger group, only one of those showed sensitivity within the older age group and only this item was retained, resulting in a total selection of seven items for the short form scale covering all of the original MDRS-22 domains.

Factor analysis of these seven items revealed the presence of a single underlying domain that satisfied criteria determined by the parallel analysis; eigenvalues were required to exceed 1.16. As shown in Table 2, all items demonstrated a moderate-to-strong loading on the underlying component except for those measuring alcohol and drug use, which loaded weakly. When modelling these 7-items using CFA at Time 2, the initial solution

1  
2  
3 280 specifying all items loading on a single latent MDRS-7 factor was not quite adequate [ $\chi^2(14)$   
4 281 = 62.23  $p < .001$ , CFI = 0.96, TLI = .94, RMSEA = 0.10 (.077-.128), SRMR = .10]. However,  
5 282 allowing the errors of the two items assessing anger and physical aggression to covary  
6  
7 283 resulted in excellent model fit [ $\chi^2(13) = 28.08$   $p = .04$ , CFI = 0.99, TLI = .98, RMSEA = .059  
8 284 (.028-.089), SRMR = .085].  
9  
10  
11  
12  
13  
14  
15

16 286 -----  
17  
18 287 Insert Table 2 about here  
19 288 -----  
20  
21  
22

23 290 *Cut-off scores for the short scale*

24 291 The proportion of men in each of the different MDRS-7 symptom severity categories  
25 292 are shown in Supplementary Figure 1 for the total sample, and by age group. As can be  
26 293 seen, older men appear more likely to be in the ‘low’ category of symptoms, and less likely  
27 294 to be in the ‘severe’ or ‘extremely severe’ categories compared to younger males. Figure 1  
28 295 shows the effect of age and MDRS-7 categories on prototypic depression (PHQ-9) and  
29 296 psychological distress (K10). For PHQ-9, there were significant differences between all  
30 297 MDRS-7 groups [ $f(3, 921) = 208.04$ ,  $p < .001$ ] and between age groups [ $f(1, 921) = 28.45$ ,  $p < .001$ ],  
31 298 with no significant interaction between MDRS-7 and age [ $f(3, 921) = 0.45$ ,  $p = .71$ ]. For  
32 299 the K10, results were similar: significant differences between all MDRS-7 groups [ $f(3,921) =$   
33 300 190.93,  $p < .001$ ] and between younger and older men [ $f(1,921) = 34.77$ ,  $p < .001$ ], but no  
34 301 interaction between MDRS-7 and age [ $f(3, 921) = 0.43$ ,  $p = .73$ ].  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 304 -----  
48 305 Insert Figure 1 about here  
49 306 -----  
50  
51  
52

53 307 *Clinical utility of the MDRS-7*

54 308 The proportion of males according to depressive classification type is shown in  
55 309 Supplementary Figure 2. Externalised-only depression affected approximately 10% of  
56  
57  
58  
59  
60

younger and older males, whilst prototypical and mixed depressive symptoms were more common in younger males. Table 3 shows the risk of mental illness and suicidality compared to non-depressed participants within each age group after controlling for a previous diagnosis of depression. All classifications were associated with both outcome measures. Individuals with mixed symptoms undoubtedly have the highest risk of suicidality and mental illness.

---

Insert Table 3 about here

---

A final GLM considered the likelihood of being classified as depressed at follow-up based on responses to the PHQ-9 (i.e., score  $\geq 10$ ). MDRS-7 category was entered as a predictor controlling for PHQ-9 scores at time 1, previous diagnosis of depression and age. As shown in Table 4, PHQ scores at time 1 were significantly associated with increased risk of depression at time 2 although age and prior diagnoses were not significantly associated. Those classified as having moderate MDRS-7 symptoms at time 1 were significantly more likely than those in the low symptom category to be classified as depressed at Time 2, whilst the severe and extremely severe categories were not associated with increased risk.

---

Insert Table 4 about here

---

## Discussion

Clinical reports and emergent empirical work suggest that men's depression may be under-detected as a result of prototypic screening tools that may be insensitive to men's gender role socialisation [11, 13, 42]. The Male Depression Risk Scale (MDRS-22) assesses male-specific, externalised symptoms of depression, such as substance misuse, risk-taking, and anger. However, in its current 22-item form, it is impractical for rapid use in primary care, particularly when used alongside traditional depression screening tools [12]. The

present research aimed to derive a short form of the MDRS-22, examine its psychometric properties and relationship with psychological distress and depression in order to demonstrate its utility as a potential screening tool in primary and other health care settings.

The short form derived herein comprises seven items, representing 1 item for each of the original MDRS domains including emotion suppression, risk-taking, substance use, drug use, somatic symptoms, and two items for the anger and aggression domain, based on criteria including variability within items, the item’s relationship to its original MDRS domain but also with the overall MDRS score. Five of the seven items demonstrated moderate-to-strong loadings on a single underlying construct presumed to reflect the male depression phenotype, whilst two items assessing alcohol and drug use loaded weakly. This likely reflects the reduced variability of participant responses on these items, with most participants reporting that these items applied to them none, or a little of the time. However, despite these lower loadings, items that tap these behaviours are important to retain given that substance use is an important marker of depression and suicidality in men and particularly those who adhere to masculine norms [42, 43].

In the present study, externalising symptoms, either alone or in combination with prototypic symptoms, were found to be significantly more common than exclusively prototypic symptoms. Approximately 10% of younger and older males were found to present with uniquely externalising symptoms, whilst approximately 40% of younger males and 10% of older males presented with mixed symptoms. These findings are consistent with previous research using the MDRS-22 [24] and highlights the potential utility of the MDRS-7 for detecting additional cases of men at risk. These men are a subset who score below threshold on traditional prototypic measures, but whose degree of externalised behaviours may be problematic. Furthermore, despite the absence of clinically elevated prototypic symptoms, both younger and older males in the mixed symptom group had a significantly higher risk of a mental illness after controlling for a previous diagnosis of depression, demonstrating unequivocally that this represents a unique group of at-risk men experiencing psychological distress. Similarly, both younger and older males in the mixed symptom group had a significantly elevated risk of suicidality. These findings are consistent



with research by Zajac and colleagues [24] and highlight the clinical importance of considering a broad range of potential presentations of depression in men, all of which are associated with increased risk of poor outcomes.

The MDRS-7 was also shown to be effective at predicting depression at a later time point, suggesting a possible prodromal effect. These findings are consistent with those by [44] who demonstrated that externalising symptoms predicted a future depressive episode in men. Hence, our findings may reflect early symptom expression, or even attempts of men to cope with what has the potential to develop into a threshold depressive disorder. This further highlights the potential value of screening for externalising symptoms to facilitate early intervention and prevention of further mental health issues [45]. In addition, given the externalised nature of male-typical symptoms of depression, it is important to note that these symptoms not only affect men's health and wellbeing but also the health wellbeing of their families, friends, and communities [13, 46, 47]. Hence the better identification and management of male depression is likely to have substantial public health implications.

### **Clinical implications**

There is an urgent need for health services and providers to utilise more sensitive diagnostic tools as a means of improving the detection of depression and psychological distress in males and addressing the high rates of male suicide [13]. The use of brief tools such as the MDRS-7 may assist with detecting unique cases of men who would score below threshold on measures such as the PHQ-9. However, an added benefit of using this scale alongside prototypic measures, is the ability to detect men presenting with mixed symptomology whose risk of suicide and poor mental health outcomes is significantly elevated. Therefore, the clinical utility of this measure may extend beyond screening and detection and into the therapy setting where it is necessary to determine, monitor, and manage differing degrees of suicidality.

### **Limitations and future research**

The methodology adopted in this study is not without limitations. The use of an online community sample of Australian males limits the generalisability of the findings to



1  
2  
3 400 other populations. Future research should examine the psychometric properties of the  
4  
5 401 MDRS-7 with additional populations, including clinical samples of men presenting to primary  
6  
7 402 care. In addition, as data was self-report, diagnosis of depression could not be verified at  
8  
9 403 clinical interview. The results of this study would be strengthened by a more rigorous  
10  
11 404 assessment of psychopathology and comorbidity. It is also important to acknowledge that  
12  
13 405 this study used a single item from the PHQ-9 to examine current suicidal ideation.  
14  
15 406 Therefore, there is a need for additional research to examine the relationship between the  
16  
17 407 MDRS-7 and other measures of suicidality, including recent suicide attempt.  
18  
19 408

20 409 **Conclusion**

21  
22 410 The present study provides important information on the development and  
23  
24 411 validation of the MDRS-7. Specifically, this study demonstrates that the MDRS-7 is a valid  
25  
26 412 and reliable measure of externalising and male-typical depression symptoms in both  
27  
28 413 younger and older men in terms of its psychometric properties as well as its sensitivity to  
29  
30 414 prototypic depression symptoms, psychological distress, and suicidality. Use of male-specific  
31  
32 415 measures of depression such as the MDRS-7 may improve the detection of depression and  
33  
34 416 suicide risk in men, and adjunctive use (alongside established prototypical scales such as the  
35  
36 417 PHQ-9) may contribute to improved public health outcomes.  
37  
38 418

38 419 **Acknowledgements**

39  
40 420 The authors thank all participants for contributing to this study. The authors would also like  
41  
42 421 to acknowledge Lynn Ward for her valuable suggestions on earlier drafts of the manuscript.  
43  
44 422

45 422 **Author contributions**

46  
47 423 D.H., S.R., and I.Z. developed the study concept. D.H. and I.Z. performed the data analyses.  
48  
49 424 D.H. drafted the paper and S.R. and I.Z. provided critical revisions. All authors approved the  
50  
51 425 final version of the paper for submission.  
52  
53 426

54 427 **Funding**

55  
56 428 D.H. is supported by an Australian Government Research Training Program Scholarship and  
57  
58  
59  
60

Table 1. Sociodemographic characteristics of participants at Time 1

Variable	Younger men ( $< 65$ )	Older men ( $\geq 65$ )
<i>n</i>	514	444
Age range	18-64	65-93
Age, <i>M</i> ( <i>SD</i> )	45.5 (14.5)	72.8 (5.9)
Relationship status, <i>n</i> (%)		
Single (never married)	119 (23.2)	12 (2.7)
Widowed/divorced/separated	70 (13.6)	95 (21.4)
Married/de-facto	323 (62.8)	334 (75.2)
Prefer not to say	2 (0.4)	3 (0.7)
Employment status, <i>n</i> (%)		
Employed full-time	227 (44.2)	22 (5.0)
Employed part-time	38 (7.4)	18 (4.1)
Employed casually	67 (13.0)	14 (3.2)
Not employed or unpaid work	97 (18.9)	13 (2.9)
Retired	73 (14.2)	375 (84.5)

a CSIRO Supplementary Scholarship. S.R. is supported by an NHMRC Career Development Fellowship (GNT1158881) from the Australian Government. These funding bodies had no influence on the design of the study and collection, analysis, or interpretation of data or in writing the manuscript.

### **Ethics approval**

Ethics approval was obtained from the University of Adelaide Human Research Ethics Committee and the CSIRO Health and Medical Human Research Ethics Committee (approval number H-2019-109). All participants provided informed consent.

### **Competing interests**

The authors declare that they have no competing interests.

### **Data sharing statement**

Data is available upon reasonable request.

Prefer not to say	12 (2.3)	2 (0.5)
Household income, <i>n</i> (%)		
<\$35,000	139 (27.0)	143 (32.2)
\$35,000-\$65,000	92 (17.9)	159 (35.8)
\$65,000-\$105,000	100 (19.5)	80 (18.0)
\$105,000-\$160,000	97 (18.9)	31 (7.0)
>\$160,000	65 (12.6)	12 (2.7)
Prefer not to say	21 (4.1)	19 (4.3)
Highest level of education, <i>n</i> (%)		
Year 11 or below	50 (9.7)	83 (18.7)
Year 12	52 (10.1)	49 (11.0)
Certificate/diploma	156 (30.4)	133 (30.0)
Bachelor's degree	139 (27.0)	76 (17.1)
Graduate certificate/diploma	44 (8.6)	39 (8.8)
Postgraduate degree	72 (14.0)	56 (12.6)
Prefer not to say	1 (0.2)	8 (1.8)

*Note.* Time 2 *n*'s (younger men = 167; older men = 173).

% may not equal 100% due to rounding.

448 Table 2. Item loadings derived from Principal Components Analysis, and Cronbach's Reliability Alpha

Domains	Items	18-64	65+	Overall	Time 2
Emotion Suppression	I bottled up my negative feelings	0.53	0.61	0.60	0.65
Alcohol Use	I needed alcohol to help me unwind	0.29	0.30	0.34	0.38
Somatic Symptoms	I had unexplained aches and pains	0.42	0.44	0.46	0.64
Aggression	I overreacted to situations with aggressive behaviour	0.68	0.74	0.69	0.30
Anger	It was difficult to manage my anger	0.76	0.73	0.74	0.65
Drug Use	Using drugs provided temporary relief	0.22	0.31	0.28	0.47
Risk-Taking	I stopped caring about the consequences of my actions	0.47	0.50	0.52	0.77
	<i>Eigenvalue</i>	2.52	2.73	2.71	
	<i>Variance explained (%)</i>	36.00	38.90	38.80	
	<i>Cronbach's alpha</i>	.69	.73	.73	
	<i>Correlation with MDRS-22</i>	.94	.94	.94	
	<i>Short form re-test reliability</i>	.70	.69	.70	
	<i>M (SD)</i>	5.9 (4.0)	3.5 (3.4)	4.8 (3.9)	

449 Note. Time 2 loadings derived using Confirmatory Factor Analysis (CFA) in the combined sample.

450

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 3. Odds of mental illness and current suicidality controlling for previous diagnosis of depression

		Not depressed	Prototypical depression	Externalised depression	Mixed depression
18-64	Depressed group, <i>n</i>	193	71	49	187
	Moderate mental illness, <i>n</i> (%)	11 (6%)	56 (79%)	10 (20%)	163 (87%)
	OR (95% CI)	1	54.77 (23.5 - 127.9)	4.24 (1.7 - 10.9)	95.23 (44.8 - 202.2)
	Suicidality, <i>n</i> (%)	13 (7%)	43 (61%)	9 (18%)	137 (73%)
	OR (95% CI)	1	19.01 (9.0 - 40.0)	3.1 (1.2 - 7.7)	33.2 (17.2 - 64.2)
65+	Depressed group, <i>n</i>	310	20	45	54
	Moderate mental illness, <i>n</i> (%)	5 (2%)	8 (40%)	6 (13%)	36 (67%)
	OR (95% CI)	1	30.24 (8.3 - 109.6)	8.0 (2.3 - 27.7)	106.01 (36.8 - 305.1)
	Suicidality, <i>n</i> (%)	19 (6%)	8 (40%)	11 (24%)	41 (76%)
	OR (95% CI)	1	8.3 (3.0 -23.5)	4.5 (1.9 - 10.3)	43.2 (19.7 - 94.8)

Note. OR for previous depression diagnosis not shown.  
Mental illness defined as K10 ≥ 25.  
Suicidality defined as ≥ 1 on PHQ-9 item 9.

468 Table 4. Odds of being classified as depressed at follow up

Outcome: Depressed (PHQ-9  $\geq 10$ ) at Time 2 ( $n = 340$ )

	OR	CI	
Age (older)	1.39	0.671	2.875
Previous depression diagnosis (yes)	1.97	0.945	4.119
PHQ-9 T1	1.25**	1.158	1.342
Moderate (MDRS-7)	2.76**	1.185	6.437
Severe (MDRS-7)	1.74	0.679	4.458
Extremely severe (MDRS-7)	1.44	0.258	8.051

Note. Reference category = low symptoms.

\*\* $p < .01$ .

Figure 1. Effect of age and MDRS-7 category on prototypic depression symptoms (PHQ-9) and psychological distress (K10)

References

1. Friedrich, M.J., *Depression is the leading cause of disability around the world*. JAMA, 2017. **317**(15): p. 1517-1517.
2. Costantini, L., et al., *Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review*. Journal of Affective Disorders, 2021. **279**: p. 473-483.
3. World Health Organization, *Depression and Other Common Mental Disorders: Global Health Estimates*, W.H. Organization, Editor. 2017, World Health Organization: Geneva.
4. Chesney, E., G.M. Goodwin, and S. Fazel, *Risks of all-cause and suicide mortality in mental disorders: A meta-review*. World Psychiatry, 2014. **13**(2): p. 153-160.
5. Mauvais-Jarvis, F., et al., *Sex and gender: modifiers of health, disease, and medicine*. The Lancet, 2020. **396**(10250): p. 565-582.
6. World Health Organization, *Preventing suicide: A global imperative*. 2014, World Health Organization: Geneva.
7. American Psychiatric Association, *Diagnostic and statistical manual of mental disorders: DSM-5*. fifth ed. 2013, Arlington, VA: American Psychiatric Association.
8. World Health Organization, *International classification of diseases for mortality and morbidity statistics* 2018.
9. Whittle, E.L., et al., *Men, Depression, and Coping: Are We on the Right Path?* Psychology of men & masculinity, 2015. **16**(4): p. 426-438.
10. Cavanagh, A., et al., *Symptom endorsement in men versus women with a diagnosis of depression: A differential item functioning approach*. International Journal of Social Psychiatry, 2016. **62**(6): p. 549-559.
11. Martin, L.A., H.W. Neighbors, and D.M. Griffith, *The experience of symptoms of depression in men vs women: Analysis of the National Comorbidity Survey Replication*. JAMA Psychiatry, 2013. **70**(10): p. 1100-6.

12. Rice, S.M., et al., *Male-Type and Prototypal Depression Trajectories for Men Experiencing Mental Health Problems*. Int J Environ Res Public Health, 2020. **17**(19).
13. Call, J.B. and K. Shafer, *Gendered Manifestations of Depression and Help Seeking Among Men*. American Journal of Men's Health, 2015. **12**(1): p. 41-51.
14. Australian Bureau of Statistics, *Health Service Usage and Health Related Actions, Australia, 2014-15 (Cat. No. 4364.0.55.002)*. 2017, Australian Bureau of Statistics: Canberra.
15. Australian Institute of Family Studies, *Mental health of Australian males: Depression, suicidality and loneliness*. 2020.
16. Martin, S., et al., *Effect of depression on health service utilisation in men: a prospective cohort study of Australian men aged 35 to 80 years*. BMJ Open, 2021. **11**(3): p. e044893.
17. Wang, Y., et al., *Do men consult less than women? An analysis of routinely collected UK general practice data*. BMJ Open, 2013. **3**(8): p. e003320.
18. Schaffer, A., et al., *Population-based analysis of health care contacts among suicide decedents: identifying opportunities for more targeted suicide prevention strategies*. World Psychiatry, 2016. **15**(2): p. 135-145.
19. Lakkis, N.A. and D.M. Mahmassani, *Screening instruments for depression in primary care: A concise review for clinicians*. Postgraduate Medicine, 2015. **127**(1): p. 99-106.
20. Brownhill, S., et al., *'For men only'. A mental health prompt list in primary care*. Australian family physician, 2003. **32**(6): p. 443.
21. Zierau, F., et al., *The Gotland Male Depression Scale: A validity study in patients with alcohol use disorder*. Nordic Journal of Psychiatry, 2002. **56**(4): p. 265-271.
22. Magovcevic, M. and M. Addis, *The Masculine Depression Scale: Development and psychometric evaluation*. Psychology of Men & Masculinity, 2008. **9**(3): p. 117-132.
23. Rice, S.M., et al., *Development and preliminary validation of the male depression risk scale: Furthering the assessment of depression in men*. Journal of Affective Disorders, 2013. **151**(3): p. 950-958.



1  
2  
3 540 24. Zajac, I.T., et al., *Suicide risk, psychological distress and treatment preferences in men*  
4 541 *presenting with prototypical, externalising and mixed depressive symptomology.*  
5 542 *Journal of Mental Health*, 2020: p. 1-8.  
6  
7 543 25. Ferenchick, E.K., P. Ramanuj, and H.A. Pincus, *Depression in primary care: part 1—*  
8 544 *screening and diagnosis.* *BMJ*, 2019. **365**: p. l794.  
9 545 26. Hutton, C. and J. Gunn, *Do longer consultations improve the management of*  
10 546 *psychological problems in general practice? A systematic literature review.* *BMC*  
11 547 *Health Services Research*, 2007. **7**(1): p. 71.  
12 548 27. The Royal Australian College of General Practitioners, *General Practice: Health of the*  
13 549 *Nation 2018.* 2018: East Melbourne, Vic.  
14 550 28. Mitchell, A.J. and J.C. Coyne, *Do ultra-short screening instruments accurately detect*  
15 551 *depression in primary care? A pooled analysis and meta-analysis of 22 studies.* *The*  
16 552 *British journal of general practice : the journal of the Royal College of General*  
17 553 *Practitioners*, 2007. **57**(535): p. 144-151.  
18 554 29. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: Validity of a brief depression*  
19 555 *severity measure.* *Journal of General Internal Medicine*, 2001. **16**(9): p. 606-613.  
20 556 30. Kessler, R.C., et al., *Short screening scales to monitor population prevalences and*  
21 557 *trends in non-specific psychological distress.* *Psychological Medicine*, 2002. **32**(6): p.  
22 558 959-976.  
23 559 31. Beck, A.T., et al., *Screening for major depression disorders in medical inpatients with*  
24 560 *the Beck Depression Inventory for Primary Care.* *Behaviour Research and Therapy*,  
25 561 1997. **35**(8): p. 785-791.  
26 562 32. Rice, S.M., et al., *Externalizing depression symptoms among Canadian males with*  
27 563 *recent suicidal ideation: A focus on young men.* *Early Intervention in Psychiatry*,  
28 564 2019. **13**(2): p. 308-313.  
29 565 33. Rice, S.M., et al., *Validity of the Male Depression Risk Scale in a representative*  
30 566 *Canadian sample: sensitivity and specificity in identifying men with recent suicide*  
31 567 *attempt.* *J Ment Health*, 2019. **28**(2): p. 132-140.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 568 34. Herreen, D., et al., *Associations between conformity to masculine norms and*  
569 *depression: age effects from a population study of Australian men.* BMC Psychology,  
570 2021. **9**(1): p. 32.
- 571 35. Kroenke, K., et al., *The Patient Health Questionnaire somatic, anxiety, and depressive*  
572 *symptom scales: A systematic review.* General Hospital Psychiatry, 2010. **32**(4): p.  
573 345-359.
- 574 36. Stolk, Y., I. Kaplan, and J. Szwarc, *Clinical use of the Kessler psychological distress*  
575 *scales with culturally diverse groups.* International Journal of Methods in Psychiatric  
576 Research, 2014. **23**(2): p. 161-183.
- 577 37. Australian Bureau of Statistics, *National Health Survey: Users' guide 2014-2015 (Cat.*  
578 *No. 4363.0).* 2019, Australian Bureau of Statistics: Canberra.
- 579 38. JASP Team, *JASP (Version 0.13.1).* 2020.
- 580 39. Pather, S. and C.S. Uys, *Using scale reduction techniques for improved quality of*  
581 *survey information.* South African journal of information management, 2008. **10**(3).
- 582 40. Stanton, J.M., et al., *Issues and strategies for reducing the length of self-report*  
583 *scales.* Personnel psychology, 2002. **55**(1): p. 167-194.
- 584 41. Hu, L.t. and P.M. Bentler, *Cutoff criteria for fit indexes in covariance structure*  
585 *analysis: Conventional criteria versus new alternatives.* Structural Equation Modeling:  
586 A Multidisciplinary Journal, 1999. **6**(1): p. 1-55.
- 587 42. Addis, M.E., *Gender and depression in men.* Clinical Psychology: Science & Practice,  
588 2008. **15**(3): p. 153-168.
- 589 43. Coleman, D., *Traditional masculinity as a risk factor for suicidal ideation: Cross-*  
590 *sectional and prospective evidence from a study of young adults.* Archives of Suicide  
591 Research, 2015. **19**(3): p. 366-384.
- 592 44. Kendler, K.S. and C.O. Gardner, *Sex differences in the pathways to major depression:*  
593 *a study of opposite-sex twin pairs.* Am J Psychiatry, 2014. **171**(4): p. 426-35.
- 594 45. Hetrick, S.E., et al., *Early Identification and Intervention in Depressive Disorders*  
595 *Towards a Clinical Staging Model.* Psychotherapy and Psychosomatics, 2008. **77**(5):  
596 p. 263-270.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

597 46. Rice, S.M., et al., *Longitudinal sex differences of externalising and internalising*  
598 *depression symptom trajectories: Implications for assessment of depression in men*  
599 *from an online study*. International Journal of Social Psychiatry, 2015. **61**(3): p. 236-  
600 240.

601 47. Wilson, S. and C.E. Durbin, *Effects of paternal depression on fathers' parenting*  
602 *behaviors: A meta-analytic review*. Clinical Psychology Review, 2010. **30**(2): p. 167-  
603 180.

604  
605  
606  
607  
608  
609  
610  
611  
612  
613

For peer review only





Figure 1. Effect of age and MDRS-7 category on prototypic depression symptoms (PHQ-9) and psychological distress (K10)


Supplementary Table 1. Descriptive and relational statistics for MDRS-22 items across younger and older age groups

Domain	Item	Younger males							Older males						
		M	SD	Skew	Total(r)	Domain(r)	Other domains(r)	Itemscore	M	SD	Skew	Total(r)	Domain(r)	Other domains(r)	Itemscore
Emotion Suppression	I tried to ignore feeling down	1.77	1.12	0.08	0.61	0.76	0.49	0	1.34	1.26	0.51	0.57	0.77	0.42	0
	I bottled up my negative feelings	1.93	1.16	0.00	0.64	0.86	0.54	4	1.28	1.15	0.58	0.73	0.86	0.58	3
	I covered up my difficulties	1.90	1.18	-0.04	0.64	0.85	0.50	1	1.21	1.21	0.64	0.71	0.84	0.55	0
	I had to work things out by myself	2.39	1.19	-0.32	0.46	0.68	0.36	1	1.96	1.36	-0.04	0.58	0.72	0.40	3
Alcohol Use	I drank more alcohol than usual	0.80	1.09	1.23	0.60	0.89	0.37	1	0.48	0.88	2.10	0.59	0.91	0.38	0
	I stopped feeling so bad while drinking	0.81	1.14	1.22	0.57	0.86	0.37	0	0.39	0.91	2.51	0.58	0.88	0.41	1
	I needed alcohol to help me unwind	0.92	1.16	1.10	0.60	0.94	0.37	4	0.52	0.93	2.01	0.61	0.94	0.37	5
	I needed to have easy access to alcohol	0.54	0.99	1.92	0.59	0.87	0.38	1	0.44	0.91	2.16	0.59	0.91	0.39	0
Somatic Symptoms	I had more heartburn than usual	0.60	0.91	1.48	0.39	0.65	0.33	0	0.38	0.71	1.88	0.50	0.70	0.41	0
	I had regular headaches	0.90	1.04	1.05	0.50	0.75	0.43	0	0.40	0.79	2.24	0.54	0.77	0.43	0
	I had stomach pains	0.72	0.90	1.06	0.54	0.75	0.44	1	0.38	0.76	2.32	0.57	0.77	0.46	1
	I had unexplained aches and pains	1.05	1.13	0.79	0.52	0.78	0.47	4	0.74	0.93	1.16	0.57	0.78	0.48	6
Anger & Aggression	I overreacted to situations with aggressive behaviour	0.59	0.82	1.42	0.51	0.83	0.46	2	0.41	0.70	1.79	0.56	0.85	0.50	4
	I verbally lashed out at others without being provoked	0.28	0.61	2.53	0.41	0.77	0.38	0	0.16	0.45	3.42	0.44	0.74	0.36	0
	I was verbally aggressive to others	0.34	0.64	2.14	0.45	0.83	0.38	0	0.20	0.49	2.82	0.41	0.80	0.33	0
	It was difficult to manage my anger	0.58	0.84	1.49	0.56	0.84	0.50	3	0.31	0.64	2.33	0.57	0.81	0.53	2
Drug Use	I sought out drugs	0.32	0.79	2.63	0.47	0.94	0.36	2	0.11	0.43	4.85	0.33	0.89	0.25	1
	I used drugs to cope	0.32	0.80	2.78	0.47	0.94	0.34	2	0.07	0.35	5.59	0.31	0.82	0.24	0
	Using drugs provided temporary relief	0.33	0.84	2.70	0.47	0.95	0.34	4	0.11	0.44	4.76	0.39	0.90	0.31	6
Risk-Taking	I drove dangerously or aggressively	0.33	0.66	2.04	0.32	0.67	0.35	0	0.12	0.37	3.12	0.32	0.61	0.29	1
	I stopped caring about the consequences of my actions	0.54	0.87	1.69	0.55	0.82	0.48	3	0.21	0.59	3.24	0.54	0.83	0.49	5
	I took unnecessary risks	0.38	0.70	1.94	0.55	0.84	0.52	3	0.15	0.45	3.19	0.47	0.82	0.43	0



Supplementary Figure 1. Proportion of participants within MDRS-7 categories

Note. Low (0 – 5), Moderate (6 – 7), Severe (8 – 12), Extremely severe (13+).



Supplementary Figure 2. Proportion of participants according to depressive symptoms classification type

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			



1	Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	6
2				
3	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates,	6
4			including periods of recruitment, exposure, follow-up,	
5			and data collection	
6				
7				
8				
9	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods	6
10			of selection of participants.	
11				
12				
13		<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors,	6-9
14			potential confounders, and effect modifiers. Give	
15			diagnostic criteria, if applicable	
16				
17				
18	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and	6-9
19	measurement		details of methods of assessment (measurement).	
20			Describe comparability of assessment methods if there	
21			is more than one group. Give information separately for	
22			for exposed and unexposed groups if applicable.	
23				
24				
25				
26				
27	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of	6
28			bias	
29				
30				
31	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	8-9
32				
33	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the	8-9
34	variables		analyses. If applicable, describe which groupings were	
35			chosen, and why	
36				
37				
38				
39	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to	8-9
40	methods		control for confounding	
41				
42				
43	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and	8-9
44	methods		interactions	
45				
46				
47	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed	8-9
48	methods			
49				
50				
51	Statistical	<a href="#">#12d</a>	If applicable, describe analytical methods taking	N/A
52	methods		account of sampling strategy	
53				
54				
55	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	N/A
56	methods			
57				
58				
59				
60				

## Results

Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for exposed and unexposed groups if applicable.	8-9
Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage	N/A
Participants	<a href="#">#13c</a>	Consider use of a flow diagram	N/A
Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	9-10
Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	8-9
Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	N/A
Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included all estimates are reported in tables	All estimates are reported in Tables
Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized	8-9
Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	<a href="#">#17</a>	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	N/A

## Discussion

1	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	12-15
2				
3				
4				
5	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	14
6				
7				
8				
9				
10	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	12-15
11				
12				
13				
14				
15				
16	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	14
17				
18				
19				
20	<b>Other</b>			
21	<b>Information</b>			
22				
23				
24	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A
25				
26				
27				
28				

29  
30 None The STROBE checklist is distributed under the terms of the Creative Commons Attribution  
31 License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool  
32 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Brief assessment of male depression in clinical care: Validation of the Male Depression Risk Scale Short Form in a cross-sectional study of Australian men

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053650.R1
Article Type:	Original research
Date Submitted by the Author:	28-Dec-2021
Complete List of Authors:	Herreen, Danielle; The University of Adelaide School of Psychology, ; Commonwealth Scientific and Industrial Research Organisation, Health & Biosecurity Rice, Simon; Orygen Youth Health; The University of Melbourne Centre for Youth Mental Health Zajac, Ian ; Commonwealth Scientific and Industrial Research Organisation, Health & Biosecurity
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	General practice / Family practice
Keywords:	Depression & mood disorders < PSYCHIATRY, PRIMARY CARE, Suicide & self-harm < PSYCHIATRY, Adult psychiatry < PSYCHIATRY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Brief assessment of male depression in clinical care:**

**Validation of the Male Depression Risk Scale Short Form in a cross-sectional study of  
Australian men**

Danielle Herreen<sup>1, 2 \*</sup>, Simon Rice<sup>3, 4</sup>, & Ian Zajac<sup>2</sup>

<sup>1</sup> School of Psychology, University of Adelaide, Adelaide, SA 5000 Australia

<sup>2</sup> Health & Biosecurity, Commonwealth Scientific & Industrial Research Organisation  
(CSIRO), Adelaide, SA 5000, Australia

<sup>3</sup> Orygen, Parkville, VIC 3052, Australia

<sup>4</sup> Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC 3052,  
Australia

\* Corresponding author information: Danielle Herreen, School of Psychology, University of  
Adelaide, Adelaide, SA 5000, Australia (email: [danielle.herreen@adelaide.edu.au](mailto:danielle.herreen@adelaide.edu.au))

**Word Count: 4170**

Abstract

**Objectives:** To develop and validate a short form of the Male Depression Risk Scale (MDRS-22) for use in primary care, examining associations with prototypic depression symptoms, psychological distress, and suicidality.

**Design:** Cross-sectional study with 8-month follow-up.

**Setting:** Community-based.

**Participants:** A community sample of younger ( $n = 510$ ; 18-64 years) and older ( $n = 439$ ; 65-93 years) males residing in Australia ( $M$  age = 58.09 years,  $SD = 17.77$ ) participated in the study. A subset of respondents ( $n = 159$  younger males;  $n = 169$  older males) provided follow-up data approximately eight months later.

**Primary and secondary outcome measures:** Quantitative data were obtained through a survey comprising a range of validated measures, including the Male Depression Risk Scale (MDRS-22), the Patient Health Questionnaire (PHQ-9), and the Kessler Psychological Distress Scale (K10). The MDRS-22 was refined using exploratory and confirmatory factor analysis in line with best practice guidelines. ANOVAs and generalised linear models were conducted to explore relationships between variables.

**Results:** The short form MDRS-22 consisted of seven items (MDRS-7) and captured all of the domains in the original tool. Participants with mixed symptoms ( $PHQ-9 \geq 10$  and  $MDRS-7 > 5$ ) had significantly higher risk of mental illness ( $K10 \geq 25$ ) and current suicidality ( $PHQ-9$  item 9  $\geq 1$ ) than those with exclusively prototypic symptoms. Furthermore, the MDRS-7 was shown to be effective at predicting elevated symptoms of depression at follow-up, after controlling for previous depression diagnoses.

**Conclusions:** Findings provide preliminary evidence of the potential utility of the MDRS-7 as a screening tool for externalised and male-type symptoms associated with major depression in men. Field trials of the MDRS-7 in primary care settings may facilitate identification of men at risk of suicide and psychological distress who do not meet cut-off scores for existing measures of major depression symptoms.

**Key words:** depression, externalising symptoms, short form, men, lifespan, help-seeking

### Strengths and limitations of this study:

- This is the first study to explore the psychometric properties of the MDRS-7 as a screening tool for externalised and male-type symptoms associated with major depression in men.
- Use of the MDRS-7 in primary care settings may facilitate identification of men at risk of suicide and psychological distress.
- Diagnosis of depression was not verified by clinical interview.
- Field trials of the MDRS-7 are needed to demonstrate the utility of the tool in primary care settings.

### Introduction

Major depressive disorder (MDD) is a common psychiatric condition and the leading cause of disability worldwide [1, 2]. MDD is twice as prevalent in women than men [3] and severe depression is known to significantly increase the risk of suicide [4]. Although men are less likely to be diagnosed with a depressive disorder [5], they are three times more likely to die by suicide compared to women [6]. Current approaches to the diagnosis of depression (e.g., as per ICD-11 or DSM-5 diagnostic criteria) emphasise symptoms including persistent sadness, loss of interest or pleasure in previously enjoyable activities, as well as changes in affect, cognition, and neurovegetative functioning [7, 8]. However, a growing number of studies suggest that a significant proportion of men suffering from depression might experience a distinct phenotype [9-11]. Congruent with masculine role norms, this male-typical phenotype includes anger, substance misuse, emotion suppression, and risk-taking domains [10, 12]. However, these putative symptoms are not included in standard diagnostic criteria or screening measures, and it has been suggested that this might account in part for the under-diagnosis of male depression cases, and therefore under-recognition of (and treatment for) men at heightened risk of suicide [13].

Whilst men are often regarded as being less likely to seek help than women, recent statistics largely do not support this claim. In Australia, around 89% of men attend primary care annually [14]. Among men experiencing mental health difficulties, annual primary care attendance is similarly high with estimates of 80% to 96% of men with symptoms of



1  
2  
3 100 depression reporting a visit to primary care within the previous 12 months [15, 16].  
4  
5 101 Similarly, findings from the UK demonstrate that whilst males are overall less likely to attend  
6  
7 102 primary care compared to females, attendance rates in men and women with comparable  
8  
9 103 underlying morbidities, including depression, are similar [17]. Furthermore, findings from a  
10  
11 104 population study of healthcare contacts among Canadian suicide decedents in Toronto  
12  
13 105 demonstrated that over 60% ( $n = 1792$ ) of men who died by suicide accessed professional  
14  
15 106 mental health care in the year before their death [18]. These findings highlight the essential  
16  
17 107 role of primary care physicians in identifying depression and suicide risk in men in order to  
18  
19 108 facilitate effective treatment [19].

20 109 Growing interest in gender-sensitive assessment of men’s depression has seen the  
21  
22 110 development of male-specific screening tools to identify symptoms that align with men’s  
23  
24 111 socialisation and gender norm processes [e.g., 20, 21, 22]. One recently developed and  
25  
26 112 widely validated measure for assessing externalising and male-type symptoms in men is the  
27  
28 113 Male Depression Risk Scale (MDRS-22) [23]. The MDRS-22 consists of 22 items assessing six  
29  
30 114 symptom domains including emotion suppression, drug use, alcohol use, anger and  
31  
32 115 aggression, somatic symptoms, and risk-taking [23]. Recently, Zajac and colleagues [24]  
33  
34 116 demonstrated that this tool, used in conjunction with a measure of prototypic depression  
35  
36 117 symptoms (PHQ-9), was able to stratify men into three distinct risk groups: (i) prototypic  
37  
38 118 symptoms (consistent with current MDD diagnostic criteria), (ii) externalising symptoms  
39  
40 119 consistent with masculine socialisation, and (iii) mixed depressive symptoms, reflecting both  
41  
42 120 internalised and externalised symptomology. Further analyses showed that men in the  
43  
44 121 externalising only group—men who are arguably missed when using measures of  
45  
46 122 internalising symptoms—were at significantly increased risk of suicide compared to non-  
47  
48 123 depressed men. Moreover, those with elevated externalised and prototypic symptomology  
49  
50 124 were at highest risk of mental illness as well as suicide [24], highlighting the potential early  
51  
52 125 identification and intervention benefits of leveraging male-specific tools in primary care  
53  
54 126 settings.

55 127 Two-stage screening methods are commonly used in primary care, and have been  
56  
57 128 shown to be effective for increasing the recognition of depression [25]. However, many  
58  
59 129 primary care physicians report that time is a limiting factor in their capacity to  
60

comprehensively assess psychological issues, including depression [19, 26], despite management of common mental disorders rating as a top reason for general practice attendance [27]. To help address this issue, brief screening tools consisting of 15 items or less are often used, given their completion time is usually just a couple of minutes [28]. Examples include the Patient Health Questionnaire (PHQ-9) [29], the Kessler Psychological Distress Scale (K10) [30], and the Beck Depression Inventory for Primary Care (BDI-PC) [31].

To date, the MDRS-22 has demonstrated excellent psychometric properties as well as the ability to detect different groups of men who may be at increased risk of suicide and mental illness [e.g., 24, 32, 33]. However, given time constraints in primary care settings, the length of the current MDRS-22 is arguably impractical [12]. The purpose of the present study was to develop a short form of the MDRS-22 to facilitate its use as a screening tool in busy and time-pressured health care settings. We also aimed to establish an initial set of cut-off scores for interpretive purposes. If the MDRS short form is to have clinical utility, it needs to be able to identify broader aspects of psychopathology. Thus, a secondary aim was to explore current and longitudinal risk of suicidality and mental illness by adopting a previously utilised categorisation according to cut-off scores on the MDRS and the widely used PHQ-9, which assesses prototypic depression symptoms [24]. Furthermore, as adherence to masculine gender norms has been found to decline as men get older [34], younger and older males were examined separately to examine the utility of the tool across age groups.

## Method

### Participants and procedure

This cross-sectional study included baseline data from a community sample of 510 younger males aged 18 to 64 years ( $M = 45.43$ ,  $SD = 14.56$ ) and 439 older males aged 65 to 93 years ( $M = 72.79$ ,  $SD = 5.88$ ). A subset of respondents ( $n = 159$  younger males;  $n = 169$  older males) participated in the follow-up component. On average, 35 weeks ( $M = 248.56$  days,  $SD = 24.59$  days) elapsed between the provision of Time 1 and Time 2. The mean age for the overall sample was 58.09 years ( $SD = 17.77$ ). Eligible participants were Australian male residents over the age of 18 years who considered themselves fluent in English.

1  
2  
3 160 Participants were recruited via paid advertisements displayed to Australian members of the  
4 161 Facebook social networking site ( $n = 601$ ; 63.3%) and through promotion of the study to  
5 162 community organisations (e.g., Rotary, Men’s Shed). Time 1 data were collected between  
6 163 August and November 2019 using an online questionnaire. However, participants from local  
7 164 community organisations were provided with the option to complete a paper version of the  
8 165 survey to ensure inclusivity and accessibility of the sample and  $n = 5$  participants completed  
9 166 a paper version. Ethics approval was obtained from the University of Adelaide Human  
10 167 Research Ethics Committee and the CSIRO Health and Medical Human Research Ethics  
11 168 Committee (approval number H-2019-109). All participants provided informed consent.  
12 169 Reporting adhered to the STROBE cross-sectional guidelines. Table 1 presents a summary of  
13 170 the characteristics of the study participants at Time 1 and Time 2.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 172 **Public involvement**

26  
27 173 Participants were not involved in the design or conduct of this research; however,  
28 174 participants could nominate to receive updates on the results of the study.  
29  
30  
31

32 176 **Measures**

33  
34  
35  
36 178 ***Demographics***

37  
38 179 Participants reported their age, gender, relationship status, employment status, level  
39 180 of education, and household income. They also reported whether they had previously been  
40 181 diagnosed with depression.  
41  
42  
43  
44

45 183 ***Male Depression Risk Scale (MDRS-22)***

46  
47 184 Externalising and male-type depression symptoms were assessed by the Male  
48 185 Depression Risk Scale (MDRS-22) [23]. The MDRS-22 contains twenty-two self-report items  
49 186 designed to assess six broad domains of externalising and male-type depression symptoms  
50 187 present in the last month including anger and aggression, drug use, alcohol use, emotion  
51 188 suppression, risk-taking, and somatic symptoms using the response format of 5-point Likert  
52 189 scale ranging from 0 (*none of the time*), 1 (*a little of the time*), 2 (*some of the time*), 3 (*most*  
53  
54  
55  
56  
57  
58  
59  
60

of the time), and 4 (*all of the time*). Cronbach's alphas for the MDRS are reported in Table 2 for both age groups and for the overall sample and are considered adequate.

### ***The Patient Health Questionnaire (PHQ-9)***

The Patient Health Questionnaire (PHQ-9) [29] is a self-report depression screening tool for use in primary care that assesses nine symptoms consistent with the DSM-5 diagnostic criteria for major depressive disorder [7]. Participants endorse how often they have experienced each symptom (e.g., "*Feeling down, depressed, or hopeless*") during the preceding two-week period using a 4-point Likert scale ranging from 0 (*not at all*) to 3 (*almost every day*). A score of 10 and above is indicative of clinically significant depressive symptoms [35]. In addition to utilising total PHQ-9 scores, we used item 9 as a measure of suicidality: "Over the past two weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself in some way?". We deemed those who scored 1 or more on this item to be currently experiencing suicidal ideation. Internal consistency of the PHQ-9 in the present study for the overall sample was high ( $\alpha = .93$ ).

### ***Kessler Psychological Distress Scale (K10)***

The Kessler Psychological Distress Scale (K10) [30] is a widely used measure in both research and primary care settings [36]. It comprises ten questions assessing a person's negative emotional state in the preceding 30 days (e.g., "*About how often did you feel so nervous that nothing could calm you down*"). Responses are based on a 5-point Likert scale ranging from 1 (*none of the time*) to 5 (*all of the time*). In addition to examining K10 total scores, we created a binary variable with scores  $\geq 25$  indicating probable mental illness, consistent with published cut-off scores for the K10 [37]. Internal consistency of the K10 in this study for the overall sample was high ( $\alpha = .95$ ).

### **Analytic sample**

A total of 1114 participants commenced the study. However, 156 participants were not included in the analyses due to substantial missing data. Thus,  $N = 949$  participants who provided complete data for the items comprising the MDRS-22 were included in the item

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

reduction process described below. Of this sample,  $n = 29$  did not provide complete data for the PHQ-9 or K10 items. Thus, models using these variables comprised  $n = 920$  participants.

**Statistical analyses**

Data for the present study were analysed using IBM SPSS Statistics (Version 26.0) except for the confirmatory factor analysis (CFA) undertaken in JASP [Version 0.13.1; 38]. Various recommendations exist for the selection of items for short-form surveys including both Rasch analysis [39] and descriptive approaches [40, 41]. Broadly speaking, the focus is on selecting items with maximum variability and which retain the theorised underlying construct—as well as sub-domains—measured by the long-form scale. Therefore, we calculated descriptive (means, standard deviation (*SD*), and skewness) and relational statistics (correlations) for each item (see Supplementary Table 1). Items were then scored based on each statistic within its corresponding domain (i.e., largest *SD*, strongest correlation etc) and summed across the different descriptive indices to derive a total performance score for each item. Parallel Analysis consisting of 1,000 permutations of the original raw data was used to determine thresholds for retaining factors. Exploratory factor analysis (EFA) of the best performing items was performed with maximum likelihood estimation within each age group, and in the combined sample. Stability of this solution was then established using CFA of Time 2 Data ( $n = 328$ ). Fit indices reported include: comparative fit index (CFI); the Tucker-Lewis index (TLI); the root mean square error of approximation (RMSEA); and the standardised root mean residual (SRMR). Interpretation of these indices were guided by the recommendations of Hu & Bentler [42].

In order to investigate the clinical utility of the reduced item scale, cut-off scores were determined for Low (0 – 5), Moderate (6 – 7), Severe (8 – 12) and Extremely severe (13+) symptom severity groups. The corresponding cumulative percentiles (cum%) at the upper boundaries of these categories were: Low (cum% = 63.5), Moderate (cum% = 77.5%), Severe (cum% = 95.5), Extremely severe (cum% = 100.0). These category scores were determined using previously reported cumulative percentiles that represented differing degrees of increased risk of recent suicide attempt for the MDRS-22 [33]. A 2x2 ANOVA was conducted to explore the effect of age group differences and MDRS-7 symptom categories

on prototypic depression (PHQ-9) and psychological distress (K10). We classified individuals into depression groups using the MDRS-7 in combination with the PHQ-9 based on previous research [24] with groups referred to as: not depressed ( $\text{PHQ-9} < 10$  and  $\text{MDRS-7} \leq 5$ ), prototypic depression features ( $\text{PHQ-9} \geq 10$  and  $\text{MDRS-7} \leq 5$ ), mixed features ( $\text{PHQ-9} \geq 10$  and  $\text{MDRS-7} > 5$ ), and externalising and male-type features ( $\text{PHQ-9} < 10$  and  $\text{MDRS-7} > 5$ ). In addition, we used the K10 to determine those individuals suffering a moderate mental illness ( $\text{K10} \geq 25$ ) from those without a mental illness ( $\text{K10} < 25$ ), and current suicidality was ascribed based on scores  $\geq 1$  on PHQ-9 item 9: "Over the past two weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself in some way?". Based on these classifications, generalised linear models (GLMs) were used to determine risk of mental illness and suicidality based on depressive symptom groupings whilst controlling for previous diagnosis of depression. An additional GLM examined risk of depression at Time 2 ( $\text{PHQ-9} \geq 10$ ) as a function of MDRS-7 categories at Time 1. Assumptions of GLMs were considered through inspection of scatter plots and histograms of residuals and predicted values, with model results reported as standardised betas.

## Results

### *Sample characteristics*

Table 1 presents the characteristics of the participants at Time 1 and Time 2. As expected, there was a higher proportion of older participants who reported themselves as married/de-facto or widowed/divorced/separated, in comparison to younger men. Regarding education, the majority of older participants completed year 11 or below, whilst the proportion of participants completing a Bachelor's degree was higher in the younger sample. In addition, household income appeared to be higher in younger compared to older men, consistent with the majority of the older sample reporting themselves as being retired. Comparisons with 2016 Australian Census data indicate that participants in the current study were more likely to be married or in a de-facto relationship (63.1% vs 58.1%), more likely to have completed a Bachelor Degree level or above (49.8% vs 22.0%), and less likely to be employed full-time (44.5% vs 57.7%) compared to the Australian population [43]. This likely reflects the trend towards older males in the current study. Sample characteristics at

Time 1 and Time 2 were mostly comparable, with a higher proportion of participants at Time 2 retired.

Insert Table 1 about here

Item reduction

Descriptive and relational statistics for each of the MDRS-22 items across younger and older age groups are displayed in Supplementary Table 1. For the emotion suppression, alcohol use, somatic symptoms, and drug use domains, a single highest scoring item emerged congruent across age groups. For the anger and aggression domain, two different items were retained because of their performance across the age groups. Finally, although two risk-taking items scored equally well in the younger group, only one of these loaded within the older age group, and only this item was retained. This resulted in a total selection of seven items for the short form scale covering all of the original MDRS-22 domains.

Factor analysis of these seven items revealed the presence of a single underlying domain that satisfied criteria determined by the parallel analysis; eigenvalues were required to exceed 1.16. As shown in Table 2, all items demonstrated a moderate-to-strong loading on a single underlying factor except for those measuring alcohol and drug use, which loaded moderately. When modelling these 7-items using CFA at Time 2, the initial solution specifying all items loading on a single latent MDRS-7 factor was not quite adequate [ $\chi^2(14) = 65.85$   $p < .001$ , CFI = 0.96, TLI = 0.94, RMSEA = 0.11 (0.08, 0.13), SRMR = 0.10]. However, allowing the errors of the two items assessing anger and physical aggression to covary resulted in acceptable model fit [ $\chi^2(13) = 29.04$   $p \leq .01$ , CFI = 0.99, TLI = .98, RMSEA = 0.06 (0.03, 0.09), SRMR = 0.09].

Insert Table 2 about here



### 310 *Cut-off scores for the short scale*

311 The proportion of men in each of the different MDRS-7 symptom severity categories  
312 are shown in Supplementary Figure 1 for the total sample, and by age group. As can be  
313 seen, older men appear more likely to be in the 'low' category of symptoms, and less likely  
314 to be in the 'severe' or 'extremely severe' categories compared to younger males. Figure 1  
315 shows the effect of age and MDRS-7 categories on prototypic depression (PHQ-9) and  
316 psychological distress (K10). For PHQ-9, there were significant differences between all  
317 MDRS-7 groups [ $F(3, 912) = 208.05, p < .001$ ] and between age groups [ $F(1, 912) = 26.76, p < .001$ ],  
318 with no significant interaction between MDRS-7 and age [ $F(3, 912) = 0.59, p = .625$ ].  
319 For the K10, results were similar: significant differences between all MDRS-7 groups [ $F(3, 912) = 188.95, p < .001$ ]  
320 and between younger and older men [ $F(3, 912) = 33.05, p < .001$ ],  
321 but no interaction between MDRS-7 and age [ $F(3, 912) = 0.44, p = .719$ ].

323 -----  
324 Insert Figure 1 about here  
325 -----

### 327 *Clinical utility of the MDRS-7*

328 The proportion of males according to depressive classification type is shown in  
329 Supplementary Figure 2. Externalised and male-type depression affected approximately 10%  
330 of younger and older males, whilst prototypic and mixed depressive symptoms were more  
331 common in younger males. Table 3 shows the risk of mental illness and suicidality compared  
332 to non-depressed participants within each age group after controlling for a previous  
333 diagnosis of depression. All classifications were associated with both outcome measures.  
334 Individuals with mixed symptoms have the highest risk of suicidality and mental illness.

336 -----  
337 Insert Table 3 about here  
338 -----



A final GLM considered the likelihood of being classified as depressed at follow-up based on responses to the PHQ-9 at Time 2 (i.e., score  $\geq 10$ ). MDRS-7 category was entered as a predictor controlling for PHQ-9 scores at Time 1, previous diagnosis of depression and age. As shown in Table 4, PHQ scores at Time 1 were significantly associated with increased risk of depression at Time 2 although age and prior diagnoses were not significantly associated. Those classified as having moderate MDRS-7 symptoms at Time 1 were significantly more likely than those in the low symptom category to be classified as depressed at Time 2, whilst the severe and extremely severe categories were not associated with increased risk.

Insert Table 4 about here

Discussion

Clinical reports and emergent empirical work suggest that men’s depression may be under-detected as a result of prototypic screening tools that may be insensitive to men’s gender role socialisation [11, 13, 44]. The Male Depression Risk Scale (MDRS-22) assesses externalised and male-type symptoms of depression, such as substance misuse, risk-taking, and anger. However, in its current 22-item form, it is impractical for rapid use in primary care, particularly when used alongside traditional depression screening tools [12]. The present research aimed to derive a short form of the MDRS-22, examine its psychometric properties and relationships with psychological distress, depression, and suicidal ideation in order to demonstrate its utility as a potential screening tool in primary and other health care settings.

The short form derived herein comprises seven items, representing 1 item for each of the original MDRS domains including emotion suppression, risk-taking, substance use, drug use, somatic symptoms, and two items for the anger and aggression domain, based on criteria including variability within items, the item’s relationship to its original MDRS domain but also with the overall MDRS score. Of particular importance is our finding that the correlation between the MDRS-7 and the original MDRS-22 was near perfect ( $r = .94$ ). Five

of the seven items demonstrated moderate-to-strong loadings on a single underlying construct presumed to reflect the male depression phenotype, whilst two items assessing alcohol and drug use loaded moderately. This likely reflects the reduced variability of participant responses on these items, with most participants reporting that these items applied to them none, or a little of the time. However, these loadings still exceeded the minimum recommended factor loading of .32 [45]. In addition, items that tap these behaviours are important to retain given that substance use is an important marker of depression and suicidality in men and particularly those who adhere to masculine norms [44, 46]. It is nonetheless important to note that substance use may reflect a comorbidity [47] or maladaptive coping [48]. These are important questions for future research to explore.

In the present study, externalising and male-type symptoms, either alone or in combination with prototypic symptoms, were found to be more common than exclusively prototypic symptoms. Approximately 10% of younger and older males were found to present with uniquely externalising and male-type symptoms, whilst 38% of younger males and 13% of older males presented with mixed symptoms. These findings are consistent with previous research using the MDRS-22 [24] and highlight the potential utility of the MDRS-7 for detecting additional cases of men at risk. Men with exclusively externalised and male-type depression are a subset who score below threshold on traditional prototypic measures but whom report a degree of externalised behaviours that might be problematic. Furthermore, both younger and older males in the mixed symptom group had increased risk of a mental illness—after controlling for a previous diagnosis of depression—demonstrating unequivocally that this represents a unique group of psychologically distressed, at-risk men. Similarly, both younger and older males in the mixed symptom group had a significantly elevated risk of suicidality. These findings are consistent with research by Zajac and colleagues [24] and highlight the clinical importance of considering a broad range of potential presentations of depression in men, all of which are associated with increased risk of poor outcomes.

The MDRS-7 was also shown to be effective at predicting depression at a later time point, suggesting a possible prodromal effect. These findings are consistent with those by

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Kendler and colleagues [49] who demonstrated that externalising and male-type symptoms predicted a future depressive episode in men. Hence, our findings may reflect early symptom expression, or even attempts of men to cope with what has the potential to develop into a threshold depressive disorder. This further highlights the potential value of screening for externalising and male-type symptoms to facilitate early intervention and prevention of further mental health issues [50]. In addition, given the externalised nature of male-typical symptoms of depression, it is important to note that these symptoms not only affect men’s health and wellbeing but also the health wellbeing of their families, friends, and communities [13, 51, 52]. Hence the better identification and management of male depression is likely to have substantial public health implications.

**Clinical implications**

There is an urgent need for health services and providers to utilise more sensitive diagnostic tools as a means of improving the detection of depression and psychological distress in males and addressing the high rates of male suicide [13]. The use of brief tools such as the MDRS-7 may assist with detecting unique cases of men who would score below threshold on measures such as the PHQ-9. However, an added benefit of using this scale alongside prototypic measures, is the ability to detect men presenting with mixed symptomology whose risk of suicide and poor mental health outcomes is significantly elevated. Therefore, the clinical utility of this measure may extend beyond screening and detection and into the therapy setting where it is necessary to determine, monitor, and manage differing degrees of suicidality.

**Limitations and suggestions for future research**

The methodology adopted in this study is not without limitations. The majority of participants were recruited online, which may limit the generalisability of the findings to other populations [53]. Future research should examine measurement invariance according to factors such as education level, income, and cultural background. There was also a trend towards older males in the current sample. However, items retained in the MDRS-7 were those that performed best in both younger and older males to ensure the measure was

appropriate across the lifespan. Future research should examine the psychometric properties of the MDRS-7 with additional populations, including clinical samples of men across the lifespan presenting to primary care. In addition, as data was self-report, diagnosis of depression could not be verified at clinical interview. The results of this study would be strengthened by a more rigorous assessment of psychopathology and comorbidity. It is also important to acknowledge that this study used a single item from the PHQ-9 to examine current suicidal ideation. Therefore, there is a need for additional research to examine the relationship between the MDRS-7 and other measures of suicidality, including recent suicide attempt.

## Conclusion

The present study provides important preliminary information on the development and validation of the MDRS-7. Specifically, this study provides emerging support for the validity and reliability of the MDRS-7 as a measure of externalising and male-type depression symptoms in both younger and older men in terms of its psychometric properties as well as its relationship to prototypic depression symptoms, psychological distress, and suicidality. Use of male-specific measures of depression such as the MDRS-7 may improve the detection of depression and suicide risk in men, and adjunctive use (alongside established prototypic scales such as the PHQ-9) may contribute to improved public health outcomes.

## Acknowledgements

The authors thank all participants for contributing to this study. The authors would also like to acknowledge Lynn Ward for her valuable suggestions on earlier drafts of the manuscript.

## Author contributions

D.H., S.R., and I.Z. developed the study concept. D.H. and I.Z. performed the data analyses. D.H. drafted the paper and S.R. and I.Z. provided critical revisions. All authors approved the final version of the paper for submission.

Table 1. Sociodemographic characteristics of participants

Variable	Younger men (< 65)		Older men (≥ 65)	
	Time 1	Time 2	Time 1	Time 2
	(n = 510)	(n = 159)	(n = 439)	(n = 169)
Age range	18-64		65-93	
Age, M (SD)	45.43 (14.56)		72.79 (5.88)	
Relationship status, n (%)				
Single (never married)	118 (23.1)	27 (17.0)	12 (2.7)	6 (3.6)
Widowed/divorced/separated	68 (13.3)	19 (11.9)	92 (21.0)	44 (26.0)
Married/de-facto	322 (63.1)	113 (71.1)	332 (75.6)	119 (70.4)
Prefer not to say	2 (0.4)	0 (0.0)	3 (0.7)	0 (0.0)
Employment status, n (%)				

**Funding**

D.H. is supported by an Australian Government Research Training Program Scholarship and a CSIRO Supplementary Scholarship. S.R. is supported by an NHMRC Career Development Fellowship (GNT1158881) from the Australian Government. These funding bodies had no influence on the design of the study and collection, analysis, or interpretation of data or in writing the manuscript.

**Ethics approval**

Ethics approval was obtained from the University of Adelaide Human Research Ethics Committee and the CSIRO Health and Medical Human Research Ethics Committee (approval number H-2019-109). All participants provided informed consent.

**Competing interests**

The authors declare that they have no competing interests.

**Data sharing statement**

Data is available upon reasonable request.

Employed full-time	227 (44.5)	66 (41.5)	22 (5.0)	5 (3.0)
Employed part-time	37 (7.3)	11 (6.9)	18 (4.1)	4 (2.4)
Employed casually	67 (13.1)	19 (11.9)	14 (3.2)	5 (3.0)
Not employed or unpaid work	94 (18.4)	24 (15.1)	13 (3.0)	7 (4.1)
Retired	73 (14.3)	39 (24.5)	370 (84.3)	148 (87.6)
Prefer not to say	12 (2.4)	0 (0.0)	2 (0.5)	0 (0.0)
Household income, <i>n</i> (%)				
<\$35,000	136 (26.7)	28 (17.6)	141 (32.1)	51 (30.2)
\$35,000-\$65,000	91 (17.8)	32 (20.1)	156 (35.5)	55 (32.5)
\$65,000-\$105,000	100 (19.6)	44 (27.7)	80 (18.2)	29 (17.2)
\$105,000-\$160,000	97 (19.0)	26 (16.4)	31 (7.1)	15 (8.9)
>\$160,000	65 (12.7)	20 (12.6)	12 (2.7)	4 (2.4)
Prefer not to say	21 (4.1)	9 (5.7)	19 (4.3)	15 (8.9)
Highest level of education, <i>n</i> (%)				
Year 11 or below	49 (9.6)	11 (6.9)	81 (18.5)	23 (13.6)
Year 12	52 (10.2)	10 (6.3)	48 (10.9)	17 (10.1)
Certificate/diploma	154 (30.2)	55 (34.6)	133 (30.3)	50 (29.6)
Bachelor's degree	139 (27.3)	44 (27.7)	74 (16.9)	34 (20.1)
Graduate certificate/diploma	43 (8.4)	15 (9.4)	39 (8.9)	20 (11.8)
Postgraduate degree	72 (14.1)	23 (14.5)	56 (12.8)	22 (13.0)
Prefer not to say	1 (0.2)	1 (0.6)	8 (1.8)	3 (1.8)

*Note.* % may not equal 100% due to rounding.

484 Table 2. Item loadings derived from exploratory factor analysis (maximum likelihood estimation)

Domains	Items	18-64	65+	Overall	Time 2
Emotion Suppression	I bottled up my negative feelings	.67	.72	.71	.68
Alcohol Use	I needed alcohol to help me unwind	.44	.45	.48	.37
Somatic Symptoms	I had unexplained aches and pains	.56	.59	.58	.63
Aggression	I overreacted to situations with aggressive behaviour	.69	.74	.71	.30
Anger	It was difficult to manage my anger	.75	.74	.75	.65
Drug Use	Using drugs provided temporary relief	.36	.44	.42	.44
Risk-Taking	I stopped caring about the consequences of my actions	.63	.62	.65	.80
	<i>Eigenvalue</i>	2.52	2.74	2.72	
	<i>Variance explained (%)</i>	36.04	39.08	38.82	
	<i>Cronbach's alpha</i>	.68	.71	.72	
	<i>Correlation with MDRS-22</i>	.94	.94	.94	
	<i>Short form re-test reliability</i>	.72	.69	.71	
	<i>M (SD)</i>	5.93 (4.04)	3.57 (3.39)	4.84 (3.93)	

485 Note. Time 2 loadings derived using confirmatory factor analysis (CFA) in the combined sample. All correlations were significant at  $p < .001$

Table 3. Odds of mental illness and current suicidality controlling for previous diagnosis of depression

	Depressed group, <i>n</i>	Moderate mental illness, <i>n</i> (%)	Moderate mental illness, AOR [95% CI]	Suicidality, <i>n</i> (%)	Suicidality, AOR [95% CI]
18-64					
Not depressed	189	11 (6)	1	13 (7)	1
Prototypic depression	69	54 (78)	51.35*** [21.94, 120.18]	42 (61)	18.76*** [8.86, 39.72]
Externalised depression	69	10 (20)	4.09** [1.60, 10.47]	9 (18)	2.99* [1.19, 7.50]
Mixed depression	186	162 (87)	91.35*** [43.00, 194.06]	136 (73)	31.97*** [16.51, 61.90]
65+					
Not depressed	308	5 (2)	1	19 (6)	1
Prototypic depression	20	8 (40)	29.66*** [8.17, 107.670]	8 (40)	8.14*** [2.89, 22.97]
Externalised depression	41	4 (10)	5.37* [1.36, 21.26]	10 (24)	4.34*** [1.83, 10.29]
Mixed depression	54	36 (67)	105.05*** [36.48, 302.50]	41 (76)	42.69*** [19.47, 93.61]

Note. Total *N* = 916 due to 4 respondents not reporting previous depression diagnosis. AOR = adjusted odds ratio. OR for previous depression diagnosis not shown. Moderate mental illness defined as K10 ≥ 25. Suicidality defined as ≥ 1 on PHQ-9 item 9. Not depressed = PHQ-9 < 10 and MDRS-7 ≤ 5; Prototypic depression = PHQ-9 ≥ 10 and MDRS-7 ≤ 5; Externalised depression = PHQ-9 < 10 and MDRS-7 > 5; Mixed depression = PHQ-9 ≥ 10 and MDRS-7 > 5.

\*\*\**p* < .001, \*\**p* < .01, \**p* < .05.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

488 Table 4. Odds of being classified as depressed at follow up

Outcome: Depressed (PHQ-9 ≥ 10) at Time 2 (n = 328)		
	OR	95% CI
Age (older)	1.46	[0.69, 3.09]
Previous depression diagnosis (yes)	1.87	[0.88, 3.99]
PHQ-9 (Time 1)	1.24***	[1.15, 1.34]
Moderate (MDRS-7)	3.30**	[1.38, 7.90]
Severe (MDRS-7)	2.00	[0.76, 5.28]
Extremely severe (MDRS-7)	1.64	[0.28, 9.54]

Note. Reference category = low symptoms. \*\*\*p < .001, \*\* p < .01.

489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502




Figure 1. Effect of age and MDRS-7 category on prototypic depression symptoms (PHQ-9) and psychological distress (K10)

References

1. Friedrich, M.J., *Depression is the leading cause of disability around the world*. JAMA, 2017. **317**(15): p. 1517-1517.

2. Costantini, L., et al., *Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review*. Journal of Affective Disorders, 2021. **279**: p. 473-483.

3. World Health Organization, *Depression and Other Common Mental Disorders: Global Health Estimates*, W.H. Organization, Editor. 2017, World Health Organization: Geneva.

4. Chesney, E., G.M. Goodwin, and S. Fazel, *Risks of all-cause and suicide mortality in mental disorders: A meta-review*. World Psychiatry, 2014. **13**(2): p. 153-160.

5. Mauvais-Jarvis, F., et al., *Sex and gender: Modifiers of health, disease, and medicine*. The Lancet, 2020. **396**(10250): p. 565-582.

6. World Health Organization, *Preventing suicide: A global imperative*. 2014, World Health Organization: Geneva.

7. American Psychiatric Association, *Diagnostic and statistical manual of mental disorders: DSM-5*. fifth ed. 2013, Arlington, VA: American Psychiatric Association.

8. World Health Organization, *International classification of diseases for mortality and morbidity statistics* 2018.

9. Whittle, E.L., et al., *Men, depression, and coping: Are we on the right path?* Psychology of men & masculinity, 2015. **16**(4): p. 426-438.

10. Cavanagh, A., et al., *Symptom endorsement in men versus women with a diagnosis of depression: A differential item functioning approach*. International Journal of Social Psychiatry, 2016. **62**(6): p. 549-559.

11. Martin, L.A., H.W. Neighbors, and D.M. Griffith, *The experience of symptoms of depression in men vs women: Analysis of the National Comorbidity Survey Replication*. JAMA Psychiatry, 2013. **70**(10): p. 1100-6.

12. Rice, S.M., et al., *Male-type and prototypal depression trajectories for men experiencing mental health problems*. Int J Environ Res Public Health, 2020. **17**(19).

13. Call, J.B. and K. Shafer, *Gendered manifestations of depression and help seeking among men*. American Journal of Men's Health, 2018. **12**(1): p. 41-51.

14. Australian Bureau of Statistics, *Health service usage and health related actions, Australia, 2014-15 (Cat. No. 4364.0.55.002)*. 2017, Australian Bureau of Statistics: Canberra.

15. Australian Institute of Family Studies, *Mental health of Australian males: Depression, suicidality and loneliness*. 2020.

16. Martin, S., et al., *Effect of depression on health service utilisation in men: a prospective cohort study of Australian men aged 35 to 80 years*. BMJ Open, 2021. **11**(3): p. e044893.

17. Wang, Y., et al., *Do men consult less than women? An analysis of routinely collected UK general practice data*. BMJ Open, 2013. **3**(8): p. e003320.

18. Schaffer, A., et al., *Population-based analysis of health care contacts among suicide decedents: identifying opportunities for more targeted suicide prevention strategies*. World Psychiatry, 2016. **15**(2): p. 135-145.

19. Lakkis, N.A. and D.M. Mahmassani, *Screening instruments for depression in primary care: A concise review for clinicians*. Postgraduate Medicine, 2015. **127**(1): p. 99-106.

20. Brownhill, S., et al., *'For men only'. A mental health prompt list in primary care*. Australian family physician, 2003. **32**(6): p. 443.

21. Zierau, F., et al., *The Gotland Male Depression Scale: A validity study in patients with alcohol use disorder*. Nordic Journal of Psychiatry, 2002. **56**(4): p. 265-271.

22. Magovcevic, M. and M. Addis, *The Masculine Depression Scale: Development and psychometric evaluation*. Psychology of Men & Masculinity, 2008. **9**(3): p. 117-132.

23. Rice, S.M., et al., *Development and preliminary validation of the Male Depression Risk Scale: Furthering the assessment of depression in men*. Journal of Affective Disorders, 2013. **151**(3): p. 950-958.
24. Zajac, I.T., et al., *Suicide risk, psychological distress and treatment preferences in men presenting with prototypical, externalising and mixed depressive symptomology*. Journal of Mental Health, 2020: p. 1-8.
25. Ferenchick, E.K., P. Ramanuj, and H.A. Pincus, *Depression in primary care: Part 1—screening and diagnosis*. BMJ, 2019. **365**: p. 1794.
26. Hutton, C. and J. Gunn, *Do longer consultations improve the management of psychological problems in general practice? A systematic literature review*. BMC Health Services Research, 2007. **7**(1): p. 71.
27. The Royal Australian College of General Practitioners, *General Practice: Health of the Nation 2018*. 2018: East Melbourne, Vic.
28. Mitchell, A.J. and J.C. Coyne, *Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies*. The British journal of general practice : the journal of the Royal College of General Practitioners, 2007. **57**(535): p. 144-151.
29. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: Validity of a brief depression severity measure*. Journal of General Internal Medicine, 2001. **16**(9): p. 606-613.
30. Kessler, R.C., et al., *Short screening scales to monitor population prevalences and trends in non-specific psychological distress*. Psychological Medicine, 2002. **32**(6): p. 959-976.
31. Beck, A.T., et al., *Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care*. Behaviour Research and Therapy, 1997. **35**(8): p. 785-791.
32. Rice, S.M., et al., *Externalizing depression symptoms among Canadian males with recent suicidal ideation: A focus on young men*. Early Intervention in Psychiatry, 2019. **13**(2): p. 308-313.
33. Rice, S.M., et al., *Validity of the Male Depression Risk Scale in a representative Canadian sample: sensitivity and specificity in identifying men with recent suicide attempt*. J Ment Health, 2019. **28**(2): p. 132-140.
34. Herreen, D., et al., *Associations between conformity to masculine norms and depression: Age effects from a population study of Australian men*. BMC Psychology, 2021. **9**(1): p. 32.
35. Kroenke, K., et al., *The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: A systematic review*. General Hospital Psychiatry, 2010. **32**(4): p. 345-359.
36. Stolk, Y., I. Kaplan, and J. Szwarc, *Clinical use of the Kessler psychological distress scales with culturally diverse groups*. International Journal of Methods in Psychiatric Research, 2014. **23**(2): p. 161-183.
37. Australian Bureau of Statistics, *National health survey: Users' guide 2014-2015 (Cat. No. 4363.0)*. 2019, Australian Bureau of Statistics: Canberra.
38. JASP Team, *JASP (Version 0.13.1)*. 2020.
39. Uddin, M.N. and F.M.A. Islam, *Psychometric evaluation of the modified Kessler seven-item version (K7) for measuring psychological distress using Rasch analysis: a cross-sectional study in a rural district of Bangladesh*. BMJ open, 2020. **10**(2): p. e034523-e034523.
40. Pather, S. and C.S. Uys, *Using scale reduction techniques for improved quality of survey information*. South African journal of information management, 2008. **10**(3).
41. Stanton, J.M., et al., *Issues and strategies for reducing the length of self-report scales*. Personnel psychology, 2002. **55**(1): p. 167-194.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

604 42. Hu, L.t. and P.M. Bentler, *Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives*. Structural Equation Modeling: A Multidisciplinary Journal, 1999. **6**(1): p. 1-55.

605

606

607 43. Australian Bureau of Statistics, *Census of population and housing - Quickstats, community profiles and datapacks user guide, Australia, 2016 (Cat. No. 2916.0)*. 2017, Australian Bureau of Statistics: Canberra.

608

609

610 44. Addis, M.E., *Gender and depression in men*. Clinical Psychology: Science & Practice, 2008. **15**(3): p. 153-168.

611

612 45. DeVellis, R.F., *Scale development: Theory and applications*. 4th ed. Applied social research methods series. Vol. 26. 2016, Thousand Oaks, Calif: Sage Publications.

613

614 46. Coleman, D., *Traditional masculinity as a risk factor for suicidal ideation: Cross-sectional and prospective evidence from a study of young adults*. Archives of Suicide Research, 2015. **19**(3): p. 366-384.

615

616

617 47. Macdonald, J.A., et al., *Profiles of Depressive Symptoms and Anger in Men: Associations With Postpartum Family Functioning*. Frontiers in psychiatry, 2020. **11**: p. 578114-578114.

618

619 48. Cavanagh, A., et al., *Differences in the expression of symptoms in men versus women with depression: A systematic review and meta-analysis*. Harvard Review of Psychiatry, 2017. **25**(1): p. 29-38.

620

621

622 49. Kendler, K.S. and C.O. Gardner, *Sex differences in the pathways to major depression: a study of opposite-sex twin pairs*. Am J Psychiatry, 2014. **171**(4): p. 426-35.

623

624 50. Hetrick, S.E., et al., *Early identification and intervention in depressive disorders: Towards a clinical staging model*. Psychotherapy and Psychosomatics, 2008. **77**(5): p. 263-270.

625

626 51. Rice, S.M., et al., *Longitudinal sex differences of externalising and internalising depression symptom trajectories: Implications for assessment of depression in men from an online study*. International Journal of Social Psychiatry, 2015. **61**(3): p. 236-240.

627

628

629 52. Wilson, S. and C.E. Durbin, *Effects of paternal depression on fathers' parenting behaviors: A meta-analytic review*. Clinical Psychology Review, 2010. **30**(2): p. 167-180.

630

631 53. Choi, I., et al., *Using different Facebook advertisements to recruit men for an online mental health study: Engagement and selection bias*. Internet Interventions, 2017. **8**: p. 27-34.

632

633

634

635

636

637

638

639

640

641

642





Figure 1. Effect of age and MDRS-7 category on prototypic depression symptoms (PHQ-9) and psychological distress (K10)

Supplementary Table 1. Descriptive and relational statistics for MDRS-22 items across younger and older age groups

		Younger males							Older males						
Domain	Item	<i>M</i>	<i>SD</i>	Skew	Total( <i>r</i> )	Domain( <i>r</i> )	Other domains( <i>r</i> )	Item score <sup>a</sup>	<i>M</i>	<i>SD</i>	Skew	Total( <i>r</i> )	Domain( <i>r</i> )	Other domains( <i>r</i> )	Item score
Emotion Suppression	I tried to ignore feeling down	1.77	1.12	0.08	.62	.77	.46	1	1.34	1.26	.51	.57	.77	.35	0
	I bottled up my negative feelings	1.93	1.16	0.01	.64	.86	.45	3	1.28	1.15	.58	.73	.86	.52	3
	I covered up my difficulties	1.90	1.18	-0.04	.64	.85	.45	2	1.21	1.21	.63	.72	.84	.51	0
	I had to work things out by myself	2.38	1.18	-0.31	.46	.68	.29	2	1.95	1.36	.04	.58	.72	.39	3
Alcohol Use	I drank more alcohol than usual	0.80	1.09	1.24	.60	.89	.34	2	0.47	0.89	.11	.59	.91	.33	0
	I stopped feeling so bad while drinking	0.80	1.14	1.22	.57	.86	.32	0	0.38	0.92	.51	.58	.88	.33	0
	I needed alcohol to help me unwind	0.92	1.16	1.10	.60	.94	.32	5	0.52	0.94	.02	.61	.94	.34	6
	I needed to have easy access to alcohol	0.53	0.98	1.93	.58	.87	.34	1	0.44	0.91	.17	.59	.91	.33	0
Somatic Symptoms	I had more heartburn than usual	0.60	0.91	1.48	.39	.65	.26	0	0.38	0.71	.87	.50	.70	.38	0
	I had regular headaches	0.89	1.04	1.07	.49	.74	.35	0	0.41	0.79	.23	.54	.77	.42	0
	I had stomach pains	0.72	0.90	1.06	.53	.74	.40	2	0.38	0.76	.33	.57	.77	.45	2
	I had unexplained aches and pains	1.05	1.13	0.80	.52	.78	.37	4	0.74	0.93	.19	.57	.78	.44	5
Anger & Aggression	I overreacted to situations with aggressive behaviour	0.59	0.83	1.41	.52	.83	.38	2	0.41	0.70	.80	.56	.85	.45	4
	I verbally lashed out at others without being provoked	0.28	0.61	2.54	.42	.77	.28	0	0.15	0.45	.44	.45	.75	.34	0
	I was verbally aggressive to others	0.34	0.65	2.13	.46	.83	.31	0	0.20	0.49	.85	.41	.80	.28	0
	It was difficult to manage my anger	0.58	0.84	1.48	.56	.84	.42	4	0.31	0.64	.35	.58	.81	.47	2
Drug Use	I sought out drugs	0.32	0.79	2.64	.47	.94	.30	3	0.11	0.43	.82	.33	.90	.23	4
	I used drugs to cope	0.32	0.81	2.79	.47	.94	.30	2	0.07	0.36	.55	.31	.83	.23	0
	Using drugs provided temporary relief	0.33	0.84	2.73	.47	.95	.29	4	0.10	0.43	.89	.40	.90	.31	4
Risk-Taking	I drove dangerously or aggressively	0.33	0.66	2.04	.33	.67	.24	0	0.12	0.37	.14	.32	.60	.27	1
	I stopped caring about the consequences of my actions	0.54	0.87	1.69	.55	.82	.46	4	0.21	0.59	.26	.54	.83	.47	5
	I took unnecessary risks	0.39	0.70	1.93	.56	.84	.46	3	0.15	0.46	.21	.47	.82	.40	0

<sup>a</sup> Items received a score of 0 or 1 (which was summed) for each statistic within its corresponding domain as follows: highest mean; largest *SD*; skew closest to zero; strongest correlation with total score; strongest correlation with domain score; and strongest correlation with other domains.






Supplementary Figure 1. Proportion of participants within MDRS-7 categories

*Note.* Low (0 – 5), Moderate (6 – 7), Severe (8 – 12), Extremely severe (13+).





Supplementary Figure 2. Proportion of participants according to depressive symptoms classification type

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			

1	Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	6
2				
3	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates,	6
4			including periods of recruitment, exposure, follow-up,	
5			and data collection	
6				
7				
8				
9	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods	6
10			of selection of participants.	
11				
12				
13		<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors,	6-9
14			potential confounders, and effect modifiers. Give	
15			diagnostic criteria, if applicable	
16				
17				
18	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and	6-9
19	measurement		details of methods of assessment (measurement).	
20			Describe comparability of assessment methods if there	
21			is more than one group. Give information separately for	
22			for exposed and unexposed groups if applicable.	
23				
24				
25				
26				
27	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of	6
28			bias	
29				
30				
31	Study size	<a href="#">#10</a>	Explain how the study size was arrived at	8-9
32				
33	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the	8-9
34	variables		analyses. If applicable, describe which groupings were	
35			chosen, and why	
36				
37				
38				
39	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to	8-9
40	methods		control for confounding	
41				
42				
43	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and	8-9
44	methods		interactions	
45				
46				
47	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed	8-9
48	methods			
49				
50				
51	Statistical	<a href="#">#12d</a>	If applicable, describe analytical methods taking	N/A
52	methods		account of sampling strategy	
53				
54				
55	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	N/A
56	methods			
57				
58				
59				
60				

## Results

Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for exposed and unexposed groups if applicable.	8-9
Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage	N/A
Participants	<a href="#">#13c</a>	Consider use of a flow diagram	N/A
Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	9-10
Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	8-9
Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	N/A
Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included all estimates are reported in tables	All estimates are reported in Tables
Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized	8-9
Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	<a href="#">#17</a>	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	N/A

## Discussion

1	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	12-15
2				
3				
4				
5	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	14
6				
7				
8				
9				
10	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	12-15
11				
12				
13				
14				
15				
16	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	14
17				
18				
19				
20	<b>Other</b>			
21	<b>Information</b>			
22				
23				
24	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A
25				
26				
27				
28				

29  
30 None The STROBE checklist is distributed under the terms of the Creative Commons Attribution  
31 License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool  
32 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60